Mammary Tumorigenesis And Malignant Progression

The current volume represents the fourth over a period of five years in our series on Advances in the Cellular and Molecular Biology of Breast Cancer. The first three volumes were entitled Breast Cancer: Cellular and Molecular Biology, Regulatory Mechanisms in Breast Cancer, and Genes, Oncogenes, and Hormones, respectively. Throughout this series, we have tried to take a broad look at cutting-edge topics in basic science research into breast cancer. This attempt has resulted in a wide range of subject material, including rodent and human model systems, oncogenes, suppressor genes, growth factors, hormones, tumor-host interactions, and determinants of metastases. Since our last volume, research in breast cancer has continued to proceed at an explosive rate. We hope the current volume will provide the reader with some of the excitement felt by the editors and authors as we begin to understand this all-too-common disease. The first section of this book is devoted to the basic processes of proli feration, differentiation, and malignant progression of breast cancer. T.l. Anderson and W.R. Miller lead off with a detailed description of controls on proliferation in the normal human breast and in breast cancer. This chapter strongly emphasizes pathological aspects. The second chapter, by M.R. Stampfer and P. Yaswen, presents a corresponding viewpoint through a presentation of experiments with human mammary epithelial cells in culture. The second section of the book emphasizes the genetic basis for breast cancer onset and malignant progression. Chapter 3, by M.-C. King and S.

Mammary Tumor Cell Cycle, Differentiation and Metastasis is the fifth volume since 1988 in a series designed to broadly examine current advances in the cellular and molecular biology of breast cancer. As in previous volumes, the editors have invited recognized experts in cutting-edge topics to provide a chapter focused on their area of research. The editors have turned to the researchers who study rodent models of the disease and to those who study the cellular and molecular basis of human breast cancer. The first section of the book is devoted to new mouse models of mammary development and tumorigenesis. The second section moves to studies of human breast cancer and focuses on receptors, signalling, and the cell cycle. The final section deals with defective tissue interactions in human breast cancer. We are now in a period of extremely rapid accumulation of data on the molecular and cellular biology of breast cancer. These findings are highlighted in chapters from Mammary Tumor Cell Cycle, Differentiation and Metastasis: Advances in Cellular and Molecular Biology of Breast Cancer.

Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates

Talks about the theme 'Personalized Breast Cancer Therapy', which covers a number of areas of general interest to breast cancer researchers including sessions on pathology and molecular profiling of breast tumors, signal transduction, receptors and hormones, tumor microenvironment, cancer stem cells and clinical therapeutics.

The idea for this book arose during the 1985 Gordon Conference on "Mammary Gland Biology". New developments in the methodology of cell biology and the explosive growth of molecular biology had begun to impact upon our understanding of mammary gland growth and function. It seemed a propitious time for summarizing the current status of knowledge of the cell and molecular biology of mammary cancer and for attempting to outline future areas of concern and interest. The reviews presented here were completed by the Fall of 1986. Although new insights will surely continue to emerge, it is hoped that the material in this volume will form not only a current update but a basic core of information for future experiments. We have not attempted to cover all areas of mammary gland transformation. Those areas where recent detailed reviews are already available have been omitted. Also, the areas of normal gland development, cell ultrastructure, hormone responsiveness, chemotherapy and clinical aspects of mammary cancer have not been included. Instead, we have selected those areas where the development of new methodology, reagents and results have led to new ideas about mammary gland function and development as they are related to neoplasia.

Resistance to therapies, both targeted and systemic, and metastases to distant organs are the underlying causes of breast cancer-associated mortality. The second edition of Breast Cancer Metastasis and Drug Resistance brings together some of the leading experts to comprehensively understand breast cancer: the factors that make it lethal, and current research and clinical progress. This volume covers the following core topics: basic understanding of breast cancer (statistics, epidemiology, racial disparity and heterogeneity), metastasis and drug resistance (bone metastasis, trastuzumab resistance, tamoxifen resistance and novel therapeutic targets, including non-coding RNAs, inflammatory cytokines, cancer stem cells, ubiquitin ligases, tumor microenvironment and signaling pathways such as TRAIL, JAK-STAT and mTOR) and recent developments in the field (epigenetic regulation, microRNAs-mediated regulation, novel therapies and the clinically relevant 3D models). Experts also discuss the advances in laboratory research along with their translational and clinical implications with an overarching goal to improve the diagnosis and prognosis, particularly that of breast cancer patients with advanced disease.

This book is aimed to summarise the key aspects of the role of circulating tumour cells (CTCs) in breast cancer, with special attention to their contribution to tumour progression and establishment of metastatic disease. We aim to give a clear overview of the knowledge about CTCs, framed in the context of breast cancer, by analysing basic and clinical research carried out so far. In a broader sense, we will address what are the main clinical needs of this disease based on its molecular heterogeneity (subtypes) and lay out the knowledge and understanding that CTCs are giving about it and how they are contributing and can still improve the better monitoring and management of breast cancer patients. We will discuss the evidences of the use of CTCs as a tool to monitor cancer progression and therapy response, based on the prognostic and predictive value they have, as well as a tool to unravel mechanisms of resistance to therapy and to identify new biomarkers allowing to predict therapy success. Moreover, we will analyse the main aspects of ongoing clinical trials and how they can contribute to determine the clinical utility of CTCs as a breast cancer biomarker. We will also touch upon general knowledge or basic notions of the biology of the metastatic process in epithelial cancers, in order to understand the origin and biology of CTCs. In this sense, we will pay special attention to EMT (epithelial to mesenchymal transition), dormancy and minimal residual disease, three key aspects that determine the outcome of the disease. We will also cover general aspects on the isolation and characterization techniques applies to the study of CTCs, and also the possibilities that the study of CTCs, as a biomarker with biological function, is opening in terms of understanding the biology of metastatic cells and the identification of therapeutic targets based on the functional and molecular characterization of CTCs. Lastly, we will try to foresee the future of CTCs in terms of clinical application and implementation in the clinical routine.